Overview
RCUS market data
Price History
RCUS price chart · 1M
- O
- 30.98
- H
- 31.06
- L
- 30.33
- C
- 30.76
- Vol
- 44,805.00
- Source
- US equities market feed
- Observed
- Aug 26, 2026, 12:00 AM
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $30.98
- Previous Close
- $31.57
- Day High
- $31.06
- Day Low
- $30.33
- 52 Week High
- $31.68
- 52 Week Low
- $20.00
- 7 Day Return
- +1.37%
- 30 Day Return
- +10.39%
- 90 Day Return
- +25.74%
- 1 Year Return
- +39.10%
- Daily Notional Volume
- $1.4M Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$3.29 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.93 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -393.2% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $10.07 – $31.74 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $3.7B · P/B 4.67 · P/S 31.69.
Company News
Wells Fargo Maintains Equal-Weight on Arcus Biosciences, Raises Price Target to $26Benzinga · Aug 6, 2026, 5:33 PM
Wedbush Maintains Outperform on Arcus Biosciences, Raises Price Target to $43Benzinga · Aug 6, 2026, 3:45 PM
Arcus Biosciences Q2 EPS $(0.72) Beats $(0.87) Estimate, Sales $41.000M Beat $23.405M EstimateBenzinga · Aug 5, 2026, 8:08 PM
Arcus Biosciences Announces A Clinical Supply Agreement With AVEO Oncology To Evaluate Casdatifan; Agreement Supports A New Randomized Cohort Within The ARC-20 Study Evaluating Investigational Casdatifan Plus Tivozanib Versus Tivozanib Alone In Patients Who Received Prior HIF-2α-inhibitor Therapy; Enrollment Expected To Begin In Q4 2026Benzinga · Jul 22, 2026, 8:48 PM
Arcus Biosciences And Summit Therapeutics Announced A Clinical Trial Collaboration To Evaluate The Safety And Efficacy Of Arcus’s Casdatifan; Data Expected to Be Generated By Mid-2027Benzinga · Jul 22, 2026, 8:34 PM
Why Did This Arcus Biosciences Analyst Bump Price Forecast by 33%?Benzinga · Jul 20, 2026, 6:45 PM
Arcus Biosciences shares are trading higher after HC Wainwright & Co. maintained its Buy rating on the stock and raised its price target from $32 to $45.Benzinga · Jul 20, 2026, 2:35 PM
HC Wainwright & Co. Maintains Buy on Arcus Biosciences, Raises Price Target to $45Benzinga · Jul 20, 2026, 10:55 AM
An Arcus Insider Sold 68,569 Shares but Kept 1.2 Million After a 200% RunThe Motley Fool · Jul 14, 2026, 11:00 AM
Arcus Biosciences Announces Publication In Nature Describing New Research From The ARC-20 Study Showing Casdatifan HIF-2a Inhibition Deeply Suppresses Serum EPO And Extends Progression-Free Survival In Advanced Kidney CancerBenzinga · Jul 1, 2026, 3:10 PM